- GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugJideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…BioSpace · 5d ago↗ source
- Expect a clash at today’s FDA peptide panelThe service members who refused the Covid vaccine, the fastest-growing Ebola outbreak in history, and other health news from Morning RoundsSTAT · 5d ago↗ source
- STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefitOn analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.STAT